Agenus (AGEN)
(Delayed Data from NSDQ)
$4.71 USD
-0.42 (-8.19%)
Updated Aug 13, 2024 04:00 PM ET
Pre-Market: $4.77 +0.06 (1.27%) 9:04 AM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.71 USD
-0.42 (-8.19%)
Updated Aug 13, 2024 04:00 PM ET
Pre-Market: $4.77 +0.06 (1.27%) 9:04 AM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Zacks News
Agenus (AGEN) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
Agenus (AGEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.
Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program
by Zacks Equity Research
Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.
Company News for May 19, 2021
by Zacks Equity Research
Companies In The News Are: WMT, TWLO, WFC, BRK.B, BMY, AGEN
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
by Zacks Equity Research
Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 12.90% and -46.27%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 9.09% and 92.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Agenus (AGEN) Q4 Earnings Expected to Decline
by Zacks Equity Research
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -7.69% and 5.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab
by Zacks Equity Research
Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.
Agenus (AGEN) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -3.70% and 188.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.
What to Expect for Applied Therapeutics (APLT) Q2 Earnings
by Zacks Equity Research
During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.
Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?
by Zacks Equity Research
On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.
Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.
Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.
Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.
Agenus (AGEN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Moving Average Crossover Alert: Agenus
by Zacks Equity Research
Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
What Makes Agenus (AGEN) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AGEN) Outperforming Other Medical Stocks This Year?
Agenus' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Agenus.